Multi-drug tolerance in Leishmania persister-like cells

Allison Aroni-Soto1,2,3, Pieter Monsieurs1,3, Odin Goovaerts4

  • 1Institute of Tropical Medicine, Experimental Parasitology Unit, Antwerp, Belgium.

Insights

Leishmaniasis treatment is challenging due to drug-tolerant "persister-like" cells. These quiescent Leishmania survive antimony exposure by reducing metabolism, showing cross-tolerance to other drugs.

Area of Science:

  • Parasitology
  • Drug Discovery
  • Cell Biology

Background:

  • Leishmaniasis is a tropical disease caused by Leishmania parasites, notoriously difficult to treat.
  • Antimony compounds remain a key treatment, but resistance is a growing concern.

Purpose of the Study:

  • To investigate the existence and characteristics of persister-like cells in Leishmania populations.
  • To understand the survival mechanisms of Leishmania under antimony drug pressure.

Main Methods:

  • Induction of persister-like cells in cultured Leishmania using lethal doses of antimony.
  • Analysis of cellular phenotypes, including proliferation, metabolism, mitochondrial membrane potential, and gene transcription.
  • Assessment of drug susceptibility and cross-tolerance in persister-like cells and resistant strains.

Main Results:

  • Leishmania persister-like cells were identified, exhibiting quiescence, reduced metabolism, and diminished mitochondrial membrane potential.
  • These persister-like cells displayed cross-tolerance to other anti-leishmanial drugs.
  • Antimony-resistant strains showed enhanced hyper-resistance after transient passage through the quiescent state.

Conclusions:

  • Leishmania exhibits remarkable adaptability to drug pressure through the formation of quiescent persister-like cells.
  • These findings underscore the need for novel anti-leishmanial drugs targeting non-proliferative parasitic forms.

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...